These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 2184006)

  • 1. Managing elevated blood lipid concentrations. Who, when and how?
    Dart AM
    Drugs; 1990 Mar; 39(3):374-87. PubMed ID: 2184006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.
    Goa KL; Barradell LB; Plosker GL
    Drugs; 1996 Nov; 52(5):725-53. PubMed ID: 9118820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The triglyceride-high-density lipoprotein axis: an important target of therapy?
    Szapary PO; Rader DJ
    Am Heart J; 2004 Aug; 148(2):211-21. PubMed ID: 15308990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of current issues in management of dyslipidemia.
    Gotto AM
    Am J Cardiol; 1993 Feb; 71(6):3B-8B. PubMed ID: 8434559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of protease inhibitor-associated hyperlipidemia.
    Penzak SR; Chuck SK
    Am J Cardiovasc Drugs; 2002; 2(2):91-106. PubMed ID: 14727985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guidelines for diagnosis and treatment of adult hyperlipidaemias. Consensus of the Belgian Lipid Club.
    Ducobu J; Daubresse JC
    Acta Clin Belg; 1994; 49(5):243-8. PubMed ID: 7992570
    [No Abstract]   [Full Text] [Related]  

  • 9. Perspectives in the treatment of dyslipidemias in the prevention of coronary heart disease.
    Borgia MC; Medici F
    Angiology; 1998 May; 49(5):339-48. PubMed ID: 9591525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Lipid risk factors of atherosclerosis: who, when, how to treat?].
    Foubert L; Dejager S; Bruckert E; Turpin G
    Ann Endocrinol (Paris); 1997; 58(4):275-82. PubMed ID: 9436473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia.
    Spencer CM; Barradell LB
    Drugs; 1996 Jun; 51(6):982-1018. PubMed ID: 8736620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Achieving optimal lipid goals in patients with coronary artery disease.
    Karalis DG; Subramanya RD; Hessen SE; Liu L; Victor MF
    Am J Cardiol; 2011 Mar; 107(6):886-90. PubMed ID: 21247526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: recommendations of the HDL Forum.
    Ascaso JF; Fernández-Cruz A; González Santos P; Hernández Mijares A; Mangas Rojas A; Millán J; Felipe Pallardo L; Pedro-Botet J; Pérez-Jiménez F; Pía G; Pintó X; Plaza I; Rubiés-Prat J;
    Am J Cardiovasc Drugs; 2004; 4(5):299-314. PubMed ID: 15449972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between isolated hypercholesterolemia, isolated hypertriglyceridemia and coronary artery disease in south Indian type 2 diabetic patients.
    Rajmohan L; Deepa R; Mohan A; Mohan V
    Indian Heart J; 2000; 52(4):400-6. PubMed ID: 11084779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low high-density lipoprotein cholesterol and other coronary heart disease risk factors in patients with total cholesterol levels greater than 5.17 mmol/L (200 mg/dL) in family practice. A report from CEN.
    J Am Board Fam Pract; 1991; 4(5):285-97. PubMed ID: 1746296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Residual dyslipidemia among United States adults treated with lipid modifying therapy (data from National Health and Nutrition Examination Survey 2009-2010).
    Wong ND; Chuang J; Wong K; Pham A; Neff D; Marrett E
    Am J Cardiol; 2013 Aug; 112(3):373-9. PubMed ID: 23642513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Behavior of the biological aging index and serum lipids in treatment with X50].
    Reuter W; Sauer I; Herrmann W
    Z Alternsforsch; 1986; 41(2):91-4. PubMed ID: 3754998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of disorders of cholesterol, triglyceride, and lipoprotein metabolism. Report 6 of the Council on Scientific Affairs.
    Arch Fam Med; 1995 Oct; 4(10):869-78. PubMed ID: 7551135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of hyperlipidemia].
    Yoshino G
    Rinsho Byori; 2002 Mar; 50(3):254-61. PubMed ID: 11985052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome.
    Vega GL; Cater NB; Hadizadeh DR; Meguro S; Grundy SM
    Clin Pharmacol Ther; 2003 Sep; 74(3):236-44. PubMed ID: 12966367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.